Woburn, MA – Curiox Biosystems Inc (Curiox) (KOSDAQ:445680), the innovator of centrifuge-free (C-FREE™) sample preparation technologies for reproducible, automated flow cytometry workflows, today announced that the Company filed a lawsuit against Becton, Dickinson and Company (BD) and Waters Corporation for trade secret misappropriation, breach of contract, and related claims in the United States District Court for the Northern District of California.

The lawsuit is based in part on the breach of an NDA signed between Curiox and BD’s Biosciences division, which was later acquired by Waters Corporation. The NDA prohibited BD Biociences from from using Curiox’s confidential information to develop a competing product, including by reverse engineering and unauthorized replication.

Curiox is seeking appropriate relief, including damages and injunctive relief to prevent further misuse of the technology the Company invented and commercialized. As the matter is now before the Court, Curiox does not intend to comment further at this time.

About Curiox Biosystems

Curiox Biosystems is a leading provider of automation platforms that enable centrifuge-free sample preparation improving efficiency, reproducibility, and assay standardization for flow cytometry workflows.

Centrifugation-based automated sample prep can place mechanical stress on cells, contributing to sample loss and variability. Building on the company’s foundational Laminar Wash™ technology, Curiox’s proprietary C-FREE™ technology overcomes the challenges associated with centrifugation by using precise fluid control to enable gentle cell washing and mixing. C-FREE™ powers the Pluto Workstations, which automate flow cytometry sample preparation on one instrument, including antibody cocktailing, staining and washing. Integrated software simplifies workflow setup and execution with no scripting, helping laboratories reduce hands-on time and achieve more consistent high-throughput sample processing.

Designed to streamline sample preparation workflows on one instrument, and built to support FDA 21 CFR Part 11, Curiox’s solutions are trusted by pharmaceutical and biotechnology companies and CROs, with over 300 installs globally, enabling more efficient, reproducible and scalable laboratory operations.

For more information, visit www.curiox.com